Fc-Fused IL-2 Analog Formulation for Long-Term Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing interleukin 2 (IL-2) therapies for immune-related diseases are limited by severe toxicity and side effects, and there is a need for a formulation that maintains activity during long-term storage.
Innovation Solution
A formulation comprising a long-acting interleukin 2 analog conjugate, including a mutated sequence and a polyethylene glycol linker with an immunoglobulin Fc region, stabilized with a buffer at pH 6 to 8, and optionally containing antioxidants, surfactants, sugars, and tonicity agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high-dose interleukin 2 therapy is administered to achieve effective immune activation, then therapeutic efficacy is improved, but severe toxicity and side effects occur
Solution Approach 1:
The interleukin 2 molecule is segmented by fusing it with the Fc region of an immunoglobulin, creating a chimeric protein that separates the immunostimulatory function (IL-2 portion) from the pharmacokinetic optimization function (Fc portion). This segmentation allows the IL-2 to maintain its biological activity while the Fc region provides extended half-life and reduced immunogenicity, thereby achieving effective immune activation with reduced toxicity.
Solution Approach 2:
The invention creates a composite protein structure by combining interleukin 2 with the Fc region of an immunoglobulin (particularly IgG1, IgG2, or IgG4). This composite structure integrates the immunostimulatory properties of IL-2 with the pharmacokinetic advantages of the Fc region, including extended serum half-life, reduced immunogenicity, and potential for FcRn-mediated recycling, thereby achieving effective therapy at lower doses with reduced side effects.
2Duration of action of stationary object
If interleukin 2 is stored for long-term use, then availability for treatment is improved, but the protein loses activity due to degradation
Solution Approach 1:
The Fc region fusion creates a composite protein with enhanced structural stability. The Fc region forms a stable dimeric structure that protects the IL-2 portion from degradation during storage. This composite structure maintains conformational stability and resists proteolytic cleavage, thereby preserving biological activity during long-term storage at various temperatures including refrigerated and frozen conditions.
3Duration of action of moving object
If the half-life of interleukin 2 is extended through Fc fusion, then dosing frequency is reduced, but the molecular structure becomes more complex
Solution Approach 1:
The Fc region serves multiple functions simultaneously: it extends serum half-life through FcRn-mediated recycling, reduces immunogenicity of the IL-2 portion, provides structural stability for storage, and enables potential for further engineering (such as antibody drug conjugates or bispecific constructs). This multi-functionality justifies the increased molecular complexity by providing numerous therapeutic advantages beyond simple half-life extension.
Data Source
AI summary
The present invention relates to a formulation comprising a long-acting conjugate of an interleukin 2 analog.